Somatic mutations in chromatin remodeler genes could modify the epigenomic landscape of CLL, but they are uncommon in this malignancy in comparison to other lymphoid neoplasms. CHD2Reworked DLBCL commonly include CDKN2A deletions and MYC translocations or amplifications on top of the genomic alterations currently existing in the first CLL, but lack